Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply

Affiliations

Editorial

D R Wong et al. Aliment Pharmacol Ther. 2017 Mar.

. 2017 Mar;45(6):858-859.

doi: 10.1111/apt.13955.

¹ Department of Clinical Pharmacy, Pharmacology & Toxicology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.

No abstract available

Comment on

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC Recruitment Team. Wong DR, et al. Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12. Aliment Pharmacol Ther. 2017. PMID: 27943397 Clinical Trial.
Editorial: can we get more clinical benefit from thiopurine metabolite testing?
Fraser AG. Fraser AG. Aliment Pharmacol Ther. 2017 Mar;45(6):857-858. doi: 10.1111/apt.13942. Aliment Pharmacol Ther. 2017. PMID: 28211629 No abstract available.